These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

327 related items for PubMed ID: 18183722

  • 1. Imiglucerase treatment in Gaucher's disease.
    Shah U, Nadeem N, Husen Y, Fadoo Z.
    J Ayub Med Coll Abbottabad; 2007; 19(2):56-9. PubMed ID: 18183722
    [Abstract] [Full Text] [Related]

  • 2. Imiglucerase and its use for the treatment of Gaucher's disease.
    Weinreb NJ.
    Expert Opin Pharmacother; 2008 Aug; 9(11):1987-2000. PubMed ID: 18627336
    [Abstract] [Full Text] [Related]

  • 3. Improvement In Symptoms Of Gaucher's Disease By Enzyme Replacement Therapy.
    Mazher W, Ali J, Abubakar S, Basar S, Murtaza G.
    J Ayub Med Coll Abbottabad; 2018 Aug; 30(3):479-481. PubMed ID: 30465391
    [Abstract] [Full Text] [Related]

  • 4. [A retrospective study on enzyme replacement therapy in patients with Gaucher disease].
    Duan YL, Zhang YH, Zang Y, Shi HP, Zhang WM, Hu YM.
    Zhonghua Er Ke Za Zhi; 2006 Sep; 44(9):653-6. PubMed ID: 17217655
    [Abstract] [Full Text] [Related]

  • 5. Gaucher's disease: a review.
    Morales LE.
    Ann Pharmacother; 1996 Apr; 30(4):381-8. PubMed ID: 8729893
    [Abstract] [Full Text] [Related]

  • 6. First long-term results of imiglucerase therapy of type 1 Gaucher disease.
    Niederau C, vom Dahl S, Häussinger D.
    Eur J Med Res; 1998 Feb 21; 3(1-2):25-30. PubMed ID: 9512964
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Replacement therapy with imiglucerase for type 1 Gaucher's disease.
    Zimran A, Elstein D, Levy-Lahad E, Zevin S, Hadas-Halpern I, Bar-Ziv Y, Foldes J, Schwartz AJ, Abrahamov A.
    Lancet; 1995 Jun 10; 345(8963):1479-80. PubMed ID: 7769903
    [Abstract] [Full Text] [Related]

  • 9. [Gaucher disease type 1--therapeutic results of enzyme substitution].
    Steensberg J, Nielsen KG, Brandt NJ.
    Ugeskr Laeger; 1998 Jun 22; 160(26):3929-30. PubMed ID: 9656836
    [Abstract] [Full Text] [Related]

  • 10. [Therapeutic targets in Gaucher's disease].
    Giraldo P, Roca M.
    Med Clin (Barc); 2011 Sep 22; 137 Suppl 1():46-9. PubMed ID: 22230126
    [Abstract] [Full Text] [Related]

  • 11. Eliglustat compared with imiglucerase in patients with Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial.
    Cox TM, Drelichman G, Cravo R, Balwani M, Burrow TA, Martins AM, Lukina E, Rosenbloom B, Ross L, Angell J, Puga AC.
    Lancet; 2015 Jun 13; 385(9985):2355-62. PubMed ID: 25819691
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. A randomized trial comparing the efficacy and safety of imiglucerase (Cerezyme) infusions every 4 weeks versus every 2 weeks in the maintenance therapy of adult patients with Gaucher disease type 1.
    Kishnani PS, DiRocco M, Kaplan P, Mehta A, Pastores GM, Smith SE, Puga AC, Lemay RM, Weinreb NJ.
    Mol Genet Metab; 2009 Apr 13; 96(4):164-70. PubMed ID: 19195916
    [Abstract] [Full Text] [Related]

  • 16. Taliglucerase alfa for the treatment of Gaucher's disease.
    Haddley K.
    Drugs Today (Barc); 2012 Aug 13; 48(8):525-32. PubMed ID: 22916340
    [Abstract] [Full Text] [Related]

  • 17. [Gaucher's disease and imiglucerase in 2009/2010: what leads to a suddenly enforced prioritisation?].
    Hofstetter K, Raspe H, Stumpf S, Framke S.
    Gesundheitswesen; 2015 Feb 13; 77(2):86-92. PubMed ID: 24671892
    [Abstract] [Full Text] [Related]

  • 18. The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement.
    Cox TM, Aerts JM, Andria G, Beck M, Belmatoug N, Bembi B, Chertkoff R, Vom Dahl S, Elstein D, Erikson A, Giralt M, Heitner R, Hollak C, Hrebicek M, Lewis S, Mehta A, Pastores GM, Rolfs A, Miranda MC, Zimran A, Advisory Council to the European Working Group on Gaucher Disease.
    J Inherit Metab Dis; 2003 Feb 13; 26(6):513-26. PubMed ID: 14605497
    [Abstract] [Full Text] [Related]

  • 19. [Safety of use of velaglucerase in 2 patients with type 1 Gaucher's disease].
    Latre P, Giraldo P.
    Med Clin (Barc); 2011 Sep 13; 137 Suppl 1():39-42. PubMed ID: 22230124
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.